Table 3

Characteristics of individual patients
TACE
Patient Number Age Gender Etiology AFP # Tumors at Dx Size (cm) pre-op Within Milan Pre-TACE Growth rate (cm/mo.) Largest tumor dia by path Days to Transplant* Recur Time to Recur Reasons for TACE
A B
T1 61 M Cryptogenic 7254 1 6.3 N N/A 5 241 N X
T2 50 M HCV 27.9 1 3.5 Y 0.02 3.7 327 Y 14.5mo. X
T3 53 M HCV 27.6 1 3.5 Y N/A 5 263 N X
T4 54 M HCV 67 3 2.9, 1.6, 1 Y N/A 3 153 N X
T5 58 M HCV 4 1 7.6 N 0 7.6 82 N X
T6 59 M HCV 4 2 3.1, 3.5 N 0.03 3.5 127 N X
T7 65 F HBV 667 1 2.5 Y 0.33 2.5 167 N X
T8 68 F HCV 18 1 6 N N/A 4.7 174 N X
T9 57 M HCV 43 2 3.2, 1.8 N N/A 3.2 141 N X
T10 48 M HCV 40 4 3.5, 2.8, 2.5, 1.0 N 0.23 3.5 190 Y 6mo. X
T11 49 M HCV 2000 1 3.5 Y 0.003 3.5 73 N X
T12 53 M HCV 189 3 2.4, 0.6, 0.3 Y N/A 2.4 377 N X
T13 54 M HCV 8 5 2.1, 1.5, 1.4, 1, .7 N 0 4 241 N X
T14 58 M HCV 188 1 6.3 N 0.12 5.5 345 Y 13mo. X
T15 57 M HCV 3 3 2.8, 1.9, 1.3 Y N/A 2 263 Y 18.5mo. X
T16 62 M HBV 20 2 1.7, 1.6 Y 0 2 153 N X

A = Downstage to achieve eligibility.

B = Bridge to transplant.

* = Days from HCC diagnosis to transplant.

Zeng et al.

Zeng et al. BMC Cancer 2012 12:584   doi:10.1186/1471-2407-12-584

Open Data